Alliance Global raised the firm’s price target on Curaleaf (CURLF) to C$6.50 from C$5.50 and keeps a Buy rating on the shares. After the company reported a top and bottom line beat for Q1, the firm believes the combination of a return to healthy growth, stabilized margins and an improved balance sheet “all present an improved fundamental investment thesis,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CURLF:
- Curaleaf Files Q1 2026 Interim Financials on Form 6-K
- Curaleaf Sets June 22 Virtual Shareholder Meeting to Vote on Governance, Equity Plan and Delaware Move
- Curaleaf Adds Four 20 Pharma Co-Founder Torsten Greif to Board to Bolster European Growth
- Curaleaf Takes Full Control of Germany’s Four 20 Pharma to Bolster European Cannabis Platform
- Curaleaf Launches US$83 Million Share Repurchase Program Approved by TSX